What Is Amycretin? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Amycretin is not FDA-approved. Products sold online as amycretin, GLP-1/amylin peptides, oral amycretin, injectable amycretin, or “research use only” amycretin may carry serious safety, quality, legal, and regulatory risks.

Quick answer

Amycretin is an investigational single-molecule glucagon-like peptide-1 and amylin receptor agonist developed by Novo Nordisk. It is designed to combine GLP-1 receptor effects, such as appetite reduction and glucose control, with amylin receptor effects, such as increased satiety and reduced food intake. Amycretin is being studied for obesity, overweight, and type 2 diabetes. It is not FDA-approved, but early clinical studies show strong weight-loss signals. Published phase 1 and phase 1b/2a data report that subcutaneous amycretin produced substantial body-weight reductions over 36 weeks, and oral amycretin has also shown meaningful weight-loss effects in early studies.

Key facts about Amycretin

What is amycretin?

Amycretin is an investigational obesity and metabolic-disease drug candidate from Novo Nordisk. It is a single molecule designed to activate both GLP-1 and amylin receptor pathways.

That matters because Novo already has major GLP-1 products, including semaglutide, and is also developing amylin-based obesity strategies. Amycretin is an attempt to combine those two hormone pathways into one drug molecule.

A PubMed-indexed Lancet study on subcutaneous amycretin describes amycretin as a novel unimolecular GLP-1 and amylin receptor agonist studied in people with overweight or obesity.

A PubMed-indexed first-in-human study on oral and subcutaneous amycretin describes amycretin as a single-molecule GLP-1 receptor and amylin receptor agonist.

The key distinction:

Amycretin is not just another GLP-1. It is a dual GLP-1/amylin receptor agonist designed to target appetite and satiety through two complementary pathways.

How does amycretin work?

Amycretin activates two hormone systems:

1. GLP-1 receptor signaling
2. Amylin receptor signaling

The GLP-1 receptor side is associated with:

• Reduced appetite
• Increased satiety
• Slower gastric emptying
• Glucose-dependent insulin secretion
• Improved blood-glucose control
• Weight loss

The amylin receptor side is associated with:

• Increased fullness
• Reduced food intake
• Slower gastric emptying
• Post-meal glucose regulation
• Appetite and body-weight effects

In plain English:

Amycretin is designed to make people feel full sooner and eat less by combining GLP-1 and amylin biology in one molecule.

This makes amycretin different from GLP-1-only drugs and different from fixed-dose combinations.

The practical interpretation:

Amycretin sits in the GLP-1/amylin dual-agonist category. It is conceptually closer to a single-molecule version of GLP-1 plus amylin pharmacology than to GLP-1-only drugs like semaglutide.

What is amycretin used for?

Amycretin is being studied for obesity, overweight, and type 2 diabetes. It is not approved for any use.

| Use | Evidence level | What is known | What is not known | |---|---|---| | Obesity / overweight | Early to moderate clinical evidence | Published studies show substantial weight-loss signals in people with overweight or obesity. | Phase 3 confirmation, FDA approval, long-term safety, and real-world durability are not established. | | Type 2 diabetes | Early to moderate clinical evidence | Novo has reported positive diabetes trial data with weight loss and glycemic-control effects. | Full long-term comparative diabetes outcomes are still developing. | | Oral obesity medication | Early clinical evidence | Oral amycretin has shown meaningful weight-loss signals in early studies. | Long-term oral efficacy, tolerability, adherence, and approval are unknown. | | Injectable obesity medication | Early to moderate clinical evidence | Once-weekly subcutaneous amycretin has shown strong weight-loss signals. | Phase 3 outcomes are still needed. | | Cardiometabolic risk | Early / indirect evidence | Weight loss and metabolic effects may improve risk markers. | Dedicated cardiovascular outcomes evidence is not established. | | Anti-aging / longevity | Unsupported | Weight loss and metabolic improvement may affect health risk. | Amycretin is not an anti-aging or longevity therapy. | | Bodybuilding / casual cutting | Unsupported and medically inappropriate | Appetite and weight effects may attract misuse. | It is not a bodybuilding drug. | | Online research-use amycretin | High risk | Sellers may market GLP-1/amylin peptides online. | Quality, sterility, identity, dose, and legality may be unknown. |

What does the research show?

Subcutaneous amycretin evidence

Subcutaneous amycretin has published clinical data in people with overweight or obesity.

A PubMed-indexed Lancet phase 1b/2a study evaluated once-weekly subcutaneous amycretin up to 60 mg over a treatment period of up to 36 weeks in participants with overweight or obesity. The study reported a safety and tolerability profile consistent with GLP-1 and amylin receptor agonism and meaningful body-weight reductions.

The practical interpretation:

Subcutaneous amycretin has real clinical weight-loss data, but it remains investigational. Strong early data are not the same as FDA approval.

Oral amycretin evidence

Oral amycretin is one of the most important parts of the amycretin story.

A PubMed-indexed first-in-human phase 1 study evaluated oral and subcutaneous amycretin in adults with overweight or obesity and assessed safety, tolerability, pharmacokinetics, and body-weight effects.

Reuters reported that oral amycretin showed a 13.1% weight loss over 12 weeks in early trials, while weekly injectable amycretin produced up to 22% weight loss over 36 weeks in earlier data.

The practical interpretation:

An effective oral GLP-1/amylin drug would be commercially and clinically important, but oral amycretin still needs larger late-stage trials.

Type 2 diabetes evidence

Amycretin is also being studied in people with type 2 diabetes.

Reuters reported that Novo Nordisk’s next-generation obesity drug amycretin showed up to 14.5% weight reduction at 36 weeks in patients with type 2 diabetes and that both oral and injectable forms were tested and found to be safe and well tolerated, with mostly mild-to-moderate gastrointestinal side effects.

The practical interpretation:

Amycretin has diabetes-relevant development momentum, but detailed peer-reviewed phase 3 diabetes data and regulatory approval are still needed.

Mechanistic evidence for GLP-1 plus amylin

The dual GLP-1/amylin concept is biologically plausible because both pathways affect appetite, satiety, gastric emptying, and metabolic regulation.

A PMC mechanistic paper on amycretin discusses amycretin as a unimolecular GLP-1 and amylin receptor agonist and explains the relevance of GLP-1 and amylin receptor agonism for weight loss and glucose metabolism.

The practical interpretation:

Amycretin’s mechanism makes sense. The remaining question is whether it can deliver durable, safe, scalable results in phase 3 and real-world use.

Evidence summary

Is amycretin FDA-approved?

No. Amycretin is not FDA-approved.

There is no FDA-approved amycretin product for obesity, overweight, type 2 diabetes, weight loss, body recomposition, anti-aging, or any other use.

Novo Nordisk has moved amycretin into later-stage development, and Reuters reported that Novo planned late-stage clinical trials of both injectable and oral amycretin starting in 2026.

The key distinction:

Amycretin is promising, but it is still investigational. Clinical-trial progress is not the same as FDA approval.

Is amycretin legal?

Amycretin’s legal status depends on country, product type, prescription status, intended use, and whether it is part of a clinical trial.

For U.S. readers:

Amycretin is not FDA-approved, and online availability does not mean it is legally marketed for human therapeutic use.

The FDA has warned broadly about illegal or unverified GLP-1 drug ingredients entering the U.S. market. That concern applies especially to gray-market versions of investigational incretin drugs.

The blunt version:

Buying “research use only” amycretin online is not the same as receiving an approved metabolic medication from a legitimate pharmacy.

Is amycretin banned in sports?

Amycretin is a GLP-1/amylin receptor agonist. Anti-doping status should be checked through official resources because rules can change and amycretin is investigational.

The USADA GLP-1 athlete guide says GLP-1 drugs are not currently prohibited in sport, but WADA is monitoring and evaluating GLP-1 agonist use by athletes.

The WADA GLP-1 receptor agonist monitoring research page discusses monitoring of GLP-1 receptor agonists.

Amycretin also has amylin receptor activity, so athletes should not assume it is safe from an anti-doping perspective just because GLP-1 drugs are currently not prohibited.

The practical advice:

Athletes should verify amycretin through Global DRO, WADA, or USADA before use and should avoid unapproved online peptide products.

Safety and side effects

Amycretin has real pharmacologic activity. It should not be treated like a harmless supplement.

Common or likely side effects, based on trial data and GLP-1/amylin class patterns, may include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Decreased appetite
• Abdominal discomfort
• Dyspepsia
• Dizziness
• Injection-site reactions for injectable forms
• Possible dehydration risk from severe vomiting or diarrhea
• Possible hypoglycemia risk when combined with insulin or insulin secretagogues
• Possible gallbladder-related concerns by class analogy
• Possible pancreatitis-related concerns by class analogy
• Unknown long-term cardiovascular outcomes
• Unknown long-term rare adverse-event profile outside clinical trials

The amylin receptor activity matters.

Amylin agonism may contribute to satiety and body-weight effects, but it can also add nausea and gastrointestinal tolerability considerations. Amycretin should not be casually described as “basically Ozempic.”

A serious evaluation of amycretin should separate:

Amycretin vs similar drugs and peptides

The key distinction:

Amycretin belongs in the GLP-1/amylin dual-agonist category. It is not a GLP-1-only drug, not a GIP/GLP-1 drug, not a GLP-1/glucagon drug, and not a generic peptide supplement.

Why is amycretin sold as “research use only”?

Some online sellers may use “research use only” language to sell amycretin or amycretin-like peptides outside normal prescription channels.

That label is not a trust signal.

A serious reader should understand this distinction:

How to evaluate amycretin claims online

Bottom line

Amycretin is an investigational single-molecule GLP-1 and amylin receptor agonist being developed by Novo Nordisk for obesity and type 2 diabetes. Early clinical data show strong weight-loss signals for both once-weekly injectable amycretin and oral amycretin.

The most defensible conclusion is:

Amycretin is one of Novo Nordisk’s most important next-generation metabolic drug candidates, but it is not FDA-approved. Readers should distinguish clinical-trial amycretin from unapproved online amycretin products with uncertain identity, purity, sterility, concentration, and legal status.

FAQ

What is amycretin?

Amycretin is an investigational single-molecule GLP-1 and amylin receptor agonist developed by Novo Nordisk for obesity, overweight, and type 2 diabetes.

What does amycretin do?

Amycretin activates GLP-1 and amylin receptor pathways. It is designed to reduce appetite, increase satiety, support weight loss, and improve metabolic control.

Is amycretin FDA-approved?

No. Amycretin is not FDA-approved for obesity, type 2 diabetes, weight loss, or any other use.

Is amycretin oral or injectable?

Both oral and subcutaneous injectable amycretin have been studied in clinical trials. Neither form is FDA-approved.

Is amycretin the same as Ozempic?

No. Ozempic contains semaglutide, a GLP-1 receptor agonist. Amycretin is a dual GLP-1 and amylin receptor agonist.

Is amycretin the same as Wegovy?

No. Wegovy contains semaglutide. Amycretin is a different investigational molecule targeting GLP-1 and amylin receptors.

Is amycretin the same as CagriSema?

No. CagriSema is a fixed-dose combination of semaglutide and cagrilintide. Amycretin is a single molecule with GLP-1 and amylin receptor activity.

Does amycretin cause weight loss?

Yes, early clinical trials show meaningful weight-loss effects with amycretin. However, it is not FDA-approved, and phase 3 confirmation is still needed.

Does amycretin help type 2 diabetes?

Amycretin is being studied in type 2 diabetes and has shown promising weight-loss and glycemic-control signals, but it is not approved as a diabetes medication.

Is amycretin better than semaglutide?

Not enough public, peer-reviewed phase 3 or head-to-head evidence exists to make that conclusion. Early results are promising, but comparison claims need stronger data.

Is amycretin safe?

Amycretin has clinical-trial safety data, but it is not risk-free. Common concerns include gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, abdominal discomfort, and appetite loss. Long-term outcomes and broader real-world safety data are still developing.

Is amycretin legal in the U.S.?

Amycretin is not FDA-approved in the U.S. Online sales as a research peptide do not mean it is legally marketed for human therapeutic use.

Is amycretin banned in sports?

GLP-1 drugs are not currently prohibited according to USADA guidance, but WADA is monitoring GLP-1 agonists. Because amycretin also activates amylin receptors, athletes should verify current status through WADA, USADA, or Global DRO before use.

Why do sellers call amycretin “research use only”?

Sellers often use “research use only” language because amycretin is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with amycretin?

The biggest risks are using an investigational metabolic drug without medical supervision, confusing clinical-trial progress with approval, and buying online products with uncertain identity, purity, sterility, concentration, and safety.

Sources

1. PubMed: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist, subcutaneous phase 1b/2a study
2. Lancet: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist
3. ScienceDirect: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist
4. PubMed: Amycretin, first-in-human phase 1 oral and subcutaneous study
5. PMC: The effect of amycretin, a unimolecular GLP-1 and amylin receptor agonist
6. PubMed: Amycretin in obesity, mechanisms, clinical efficacy, and emerging evidence
7. Reuters: Novo plans late-stage trials of amycretin
8. Reuters: Novo next-generation obesity drug shows positive results
9. Diabetes Journals: Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist
10. Springer Medicine: Amycretin shows promise in early trials
11. USADA: Weight Loss Drugs, What Athletes Need to Know About GLP-1s
12. WADA: GLP-1 Receptor Agonists Monitoring Research